MNM Bioscience Inc.
The AI engine Fit Assessment
BetaMNM leverages machine learning for pattern discovery and the development of new therapeutics, while also focusing on biomarker identification to enhance personalized medicine.
Blurb
MNM integrates cutting-edge genomics with the latest breakthroughs in AI to fight cancer. Our goal is to crack the code of tumor biology
HQ Location
Cambridge (United States)
Founded
2018
Employees
33
Total funding raised
$3.29M
Last Funding Event
Seed, $2.44M, October 20, 2020
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Biomarker Identification
MNM is a scientific start-up created by an interdisciplinary group of enthusiasts. We are a multi-specialist team of experts from geneticists, to molecular biologists, bioinformaticians and AI specialists. We combine next-generation AI with the most advanced genomic approaches (whole genome and multiomics data) to save the lives of cancer patients through predictive modeling and drug target identification.